



GP/1653

TECH CENTER 1600/2600
NOV 19 2002RECEIVED
NOV 19 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:
SERIAL NO.:
FILED:
CASE NO.:
ART UNIT:
EXAMINER:

Copeland et al. :
09/808,832 :
March 15, 2001 :
PH-7134 :
1653 :
J. Russell :

**FOR: PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND
THEIR THERAPEUTIC USE**

P #9

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (X) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

Respectfully submitted,

Scott K. Larsen, Ph.D., J.D.
Attorney for Applicants
Registration No. 38,532
Telephone: 302-467-5261

DATE: Nov 15, 2002
Bristol-Myers Squibb Company
P. O. Box 4000
Princeton, NJ 08543-4000



PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Robert A. Copeland et al

CASE NO.: PH-7134

APPLICATION NO.: 09/808,832

GROUP ART UNIT: 1653

FILED: MARCH 15, 2001

EXAMINER: J. RUSSEL

FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR
THERAPEUTIC USE

I hereby certify that this correspondence, a Information Disclosure Statement, PTO Form 1449 and Postcard are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

November 15, 2002

Date

Denise Bierlein

Signature

Denise Bierlein/Depositor

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
TECH CENTER 1600/2900
NOV 19 2002